[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555152":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":29,"locations":26,"responsibleParty":35,"collaborators":26,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":26,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":26,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":26,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":26},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"topical thymoquinone ointment","EXPERIMENTAL","One plaque on one side of the body per every patient will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.",[13],"Drug: Topical thymoquinone Ointment",{"label":15,"type":16,"description":17,"interventionNames":18},"topical placebo ointment","PLACEBO_COMPARATOR","In each patient a single similar psoriatic plaque on the other side of the body \\[as regard anatomical site, size and TES (thickness, erythema, scales) score\\] will be treated with placebo ointment twice daily for 3 months as a control.",[19],"Drug: topical placebo ointment",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Topical thymoquinone Ointment","One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":28,"otherNames":26},[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":26,"email":34},"Heba Hassan, MD","CONTACT","01002866919","hebahasan16888@yahoo.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Heba Hasan Sayed","Doctor","100555152","topical-thymoquinone-in-psoriasis-vulgaris-100555152",false,"NCT06508372","Topical Thymoquinone in Psoriasis Vulgaris","Efficacy and Safety of Thymoquinone Ointment as a Potential New Therapeutic Modality of Psoriasis Vulgaris.","Inclusion Criteria:\n\n* Patients with clinical diagnosis of mild psoriasis vulgaris\n* Age: between 18 and 60 years' old\n* Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment\n\nExclusion Criteria:\n\n* Psoriasis vulgaris involving \\> 10% of the body surface area, pustular or erythrodermic psoriasis.\n* Pregnant or lactating females.\n* Patients with any current dermatological disease.\n* Patients with any current systemic disease.","ALL","18 Years","60 Years",{"count":50,"type":51},30,"ESTIMATED","INTERVENTIONAL",[54],"NA","A previous trial found that N. sativa oil was more effective as an antipsoriatic agent, particularly when taken as both a cream and a pill. This confirmed that N. sativa possesses antipsoriatic properties and can alleviate psoriasis symptoms",[57],"Psoriasis Vulgaris",[59],"topical thymoquinone","NOT_YET_RECRUITING","2024-07-18",{"date":63,"type":64},"2024-07-19","ACTUAL",{"date":66,"type":51},"2024-08-01",{"date":68,"type":51},"2025-01",{"name":5,"class":6}]